Founding Cohort 2026, 9 spots remaining · 50% off Founders Rate For Life →
Authoritize.ai
Back to Atlas
CRITICALStem Cell / Regenerative

Vitti Labs, LLC

FDA issued a warning letter to Vitti Labs, LLC, a Liberty, MO manufacturer of human umbilical cord- and amniotic membrane-derived products (EV-PURE+, WJ-PURE+, VITTI-PURE, NS-PURE, EV-OPTI DROPS), finding that these HCT/Ps are unapproved biological drug products marketed without a valid biologics license application (BLA) or investigational new drug (IND) application. The products failed to meet the homologous-use and minimal-manipulation criteria under 21 CFR 1271.10(a), and the inspection documented significant CGMP deviations including unvalidated aseptic processes, inadequate environmental monitoring, and unsupported two-year expiration dating. FDA warned that failure to adequately respond may result in seizure and/or injunction.

your products intended for injection, ophthalmic administration, and/or topical application and purport to be sterile

your products are intended for clinical use in humans to treat a variety of diseases or conditions

using these products to treat orthopedic diseases or conditions, for example, is not homologous use as defined in 21 CFR 1271.3(c)

your firm has assigned a two-year expiration date to your products without adequate data regarding the stability characteristics of the products

We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence.

Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and/or injunction.

Your response also does not adequately address your failure to have an IND in effect to study your products addressed in this letter or your lack of an approved BLA to lawfully market your products.

Does your site contain similar claims?

The free site audit scans your whole site against every entry in this Atlas. Most stem cell / regenerative sites match 3-6 patterns.

Run my free site audit

Worried about one specific page, ad, or email? Paste it into the free Claim Checker and see what the FDA and FTC would flag, with the precedent next to each one. No email required.

Check specific copy in the Claim Checker